Solid Tumor-MKGIMI BIOTECH

NCT07193966 NG2 and DLL3 CAR-T Cells Targeting Melanoma'

Estimated Enrollment:

100

NCT07180927 DLL3 CAR-T Therapy Targeting Brain Tumors'

Estimated Enrollment:

30

NCT07068555 Development of Prostate Cancer Dendritic Cell Vaccines'

Estimated Enrollment:

10

NCT05437328 GD2/CD56 Bi-specific CAR-T Cells For the Treatment of GD2 and CD56 Positive Solid Tumors'

Estimated Enrollment:

60

NCT05438368 GD2/CD70 Bi-specific CAR-T Cells For the Treatment of GD2 and CD70 Positive Solid Tumors'

Estimated Enrollment:

30

NCT05437341 PSMA/CD70 Bi-specific CAR-T Cells For the Treatment of PSMA and CD70 Positive Solid Tumors'

Estimated Enrollment:

60

NCT05437315 GD2/PSMA Bi-specific CAR-T Cells For the Treatment of GD2 and PSMA Positive Solid Tumors'

Estimated Enrollment:

60

NCT04432649 Multicenter Trial of Phase I/II Studies on CD276 (B7-H3) Positive Solid Tumors Treated With 4SCAR-276'

Estimated Enrollment:

100

NCT04433221 Safety and Efficacy Evaluation of a Combination Immunotherapy Targeting Sarcomas'

Estimated Enrollment:

20

NCT04430595 Multiple 4SCAR-T Cell Therapy Targeting Breast Cancer'

Estimated Enrollment:

100

NCT04429451 Phase I/II Clinical Trial of 4SCAR-PSMA T Cell Therapy Targeting PSMA Positive Malignancies'

Estimated Enrollment:

100

NCT04085159 Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis Type II or Schwannomatosis'

Estimated Enrollment:

100

NCT03914768 Immune Modulatory DC Vaccine Against Brain Tumor'

Estimated Enrollment:

10

NCT03614650 Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer'

Estimated Enrollment:

100

NCT03535246 Tumor Associated Antigen-specific Engineered Immune Effector Cells (EIE) Against Cancer'

Estimated Enrollment:

100

NCT03356808 Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Lung Cancer'

Estimated Enrollment:

20

NCT03362619 Engineered Immune Effectors Against Cervical Cancer'

Estimated Enrollment:

20

NCT03362606 Engineered Immune Effectors Against Ovarian Cancer'

Estimated Enrollment:

20

NCT03356795 Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer'

Estimated Enrollment:

20

NCT03356782 Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas'

Estimated Enrollment:

20

NCT03185468 Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies'

Estimated Enrollment:

20

NCT03170141 Immunogene-modified Antigen-specific T(lgT) Cells for the Treatment of Glioblastoma Multiforme'

Estimated Enrollment:

30

NCT03184753 Interventional Treatment of Ovarian Cancer(OC) With OC Immunogene-modified T Cells(OC-lgT)'

Estimated Enrollment:

100

NCT02992210 Multicenter Trial of Phase I/II Studies on GD2 Positive Solid Tumors by 4SCAR-GD2'

Estimated Enrollment:

100